Effector Therapeutics Probability of Future Stock Price Finishing Over 1.19
| EFTRDelisted Stock | USD 0.13 0.03 30.00% |
Effector |
Effector Therapeutics Target Price Odds to finish over 1.19
The tendency of Effector Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move over $ 1.19 or more in 90 days |
| 0.13 | 90 days | 1.19 | about 63.84 |
Based on a normal probability distribution, the odds of Effector Therapeutics to move over $ 1.19 or more in 90 days from now is about 63.84 (This Effector Therapeutics probability density function shows the probability of Effector Stock to fall within a particular range of prices over 90 days) . Probability of Effector Therapeutics price to stay between its current price of $ 0.13 and $ 1.19 at the end of the 90-day period is about 12.02 .
Given the investment horizon of 90 days the stock has the beta coefficient of 5.75 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Effector Therapeutics will likely underperform. Additionally Effector Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Effector Therapeutics Price Density |
| Price |
Predictive Modules for Effector Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Effector Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Effector Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Effector Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Effector Therapeutics is not an exception. The market had few large corrections towards the Effector Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Effector Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Effector Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -5.3 | |
β | Beta against Dow Jones | 5.75 | |
σ | Overall volatility | 3.05 | |
Ir | Information ratio | -0.31 |
Effector Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Effector Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Effector Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Effector Therapeutics is not yet fully synchronised with the market data | |
| Effector Therapeutics has some characteristics of a very speculative penny stock | |
| Effector Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (35.81 M) with loss before overhead, payroll, taxes, and interest of (19.76 M). | |
| Effector Therapeutics currently holds about 41.04 M in cash with (29.55 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.99, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
Effector Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Effector Stock often depends not only on the future outlook of the current and potential Effector Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Effector Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 2.2 M | |
| Cash And Short Term Investments | 18.4 M |
Effector Therapeutics Technical Analysis
Effector Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Effector Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Effector Therapeutics. In general, you should focus on analyzing Effector Stock price patterns and their correlations with different microeconomic environments and drivers.
Effector Therapeutics Predictive Forecast Models
Effector Therapeutics' time-series forecasting models is one of many Effector Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Effector Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Effector Therapeutics
Checking the ongoing alerts about Effector Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Effector Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Effector Therapeutics is not yet fully synchronised with the market data | |
| Effector Therapeutics has some characteristics of a very speculative penny stock | |
| Effector Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (35.81 M) with loss before overhead, payroll, taxes, and interest of (19.76 M). | |
| Effector Therapeutics currently holds about 41.04 M in cash with (29.55 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.99, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Stocks Directory module to find actively traded stocks across global markets.
Other Consideration for investing in Effector Stock
If you are still planning to invest in Effector Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Effector Therapeutics' history and understand the potential risks before investing.
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |